These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3680569)

  • 1. Drug absorption rate: a critical component of bioequivalence assessment in psychopharmacology.
    Greenblatt DJ; Shader RI
    J Clin Pharmacol; 1987 Feb; 27(2):85-6. PubMed ID: 3680569
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of rate of absorption in bioequivalence studies.
    Aarons L
    J Pharm Sci; 1987 Oct; 76(10):853-5. PubMed ID: 3430353
    [No Abstract]   [Full Text] [Related]  

  • 3. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.
    Ring A; Tothfalusi L; Endrenyi L; Weiss M
    Pharm Res; 2000 May; 17(5):583-8. PubMed ID: 10888310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the 1993 Veterinary Drug Bioequivalence Workshop, held on March 29-31, 1993, in Rockville, Maryland.
    J Vet Pharmacol Ther; 1994 Apr; 17(2):85-119. PubMed ID: 7913728
    [No Abstract]   [Full Text] [Related]  

  • 7. Power analyses of moment analysis parameter in bioequivalence tests.
    Kaniwa N; Ogata H; Aoyagi N; Takeda Y; Uchiyama M
    J Pharm Sci; 1989 Dec; 78(12):1020-4. PubMed ID: 2614692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved intercept method for the assessment of absorption rate in bioequivalence studies.
    Macheras P; Symillides M; Reppas C
    Pharm Res; 1996 Nov; 13(11):1755-8. PubMed ID: 8956348
    [No Abstract]   [Full Text] [Related]  

  • 9. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
    Endrenyi L; Fritsch S; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):394-9. PubMed ID: 1748540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies.
    Schall R; Hundt HK; Luus HG
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):633-7. PubMed ID: 7881699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
    Rostami-Hodjegan A; Jackson PR; Tucker GT
    J Pharm Sci; 1994 Nov; 83(11):1554-7. PubMed ID: 7891273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.
    Basson RP; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1996 Feb; 13(2):324-8. PubMed ID: 8932457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measures of exposure versus measures of rate and extent of absorption.
    Chen ML; Lesko L; Williams RL
    Clin Pharmacokinet; 2001; 40(8):565-72. PubMed ID: 11523723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies.
    Macheras P; Symillides M; Reppas C
    Pharm Res; 1994 Jun; 11(6):831-4. PubMed ID: 7937521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of generic drugs in clinical psychopharmacology.
    Greenblatt DJ; Shader RI
    J Clin Psychopharmacol; 1987 Feb; 7(1):A21-3. PubMed ID: 3818990
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.